Amgen expands QCM-D capacity

Tuesday, July 01, 2008

Within a year from their first purchase, Amgen, a leading biotech company, has ordered their second Q-Sense E4 unit to their research in human therapeutics. The purchase is the latest example of where QCM-D provides invaluable input to protein drug developers.

Protein analysis is one of Q-Sense key application areas, and this sale is a result of Q-Sense latest efforts in the field. Q-Sense technology enables researchers to analyze protein questions from a different angle, providing new and needed insights regarding protein aggregation, viscosity and protein interactions.


About Q-Sense
Q-Sense develops, produces and markets real-time analysis solutions for surface interaction measurements based on our patented technology Quartz Crystal Microbalance with Dissipation (QCM-D). Q-Sense was founded in Sweden 1996 and now has a world-wide distribution system and customers and instruments all over the world. As QCM-D has become an established method, it is now possible to find hundreds of literature references. Q-Sense instruments are utilized daily by companies and universities like Amgen, Boston Scientific, P&G, Harvard, Imperial College and ETH Zürich. Q-Sense instruments measures molecular binding events on different surfaces such as adsorptions, degradations, cell interactions and specificity of binding. Uniquely Q-Sense instruments also analyses thickness, water content and structural changes of molecular layers.